Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
ENZO BIOCHEM INC incurred revolving credit of $8 million revolving line of credit; borrowed $5.5 million upon closing with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL at Term SOFR for a three-month tenor plus 5.50% maturing after one year.
- Instrument
- revolving credit
- Principal
- $8 million revolving line of credit; borrowed $5.5 million upon closing
- Counterparty
- Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL
- Rate
- Term SOFR for a three-month tenor plus 5.50%
- Maturity
- after one year
- Event
- incurrence
Exact text from the filing
of its domestic subsidiaries, as guarantors (the “Guarantors”), and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL as lender. The Credit Facility provides for a maximum $8 million revolving line of credit. The Borrowers intend to use the borrowing proceeds under the Credit Facility for working capital and general corporate purposes. The commitment under
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ENZO BIOCHEM INC entered into Revolving Loan and Security Agreement with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL valued at maximum $8 million revolving line of credit (effective 2023-03-31).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL
- Value
- maximum $8 million revolving line of credit
- Effective
- 2023-03-31
Exact text from the filing
On March 31, 2023, Enzo Biochem, Inc. (the “Company”) entered into a Revolving Loan and Security Agreement (the “Credit Facility”) among Enzo Clinical Labs, Inc. and Enzo Life Sciences, Inc., as borrowers (the “Borrowers”), the Company and certain of its domestic subsidiaries, as guarantors (the “Guarantors”), and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL as lender.
View on SEC.gov